UK-based pharmaceutical major GlaxoSmithKline has published a list of payments it made during 2010 for clinical research studies led by US healthcare professionals.

The company listed 127 studies involving 595 lead researchers or principal investigators, with institutions receiving payments totalling $28.5m for their assistance in research surrounding various illnesses including cardiovascular disease, macular degeneration and cancers.

The payments represent a small proportion of GlaxoSmithKline’s investment into global R&D, which totalled $6.9bn in 2010.

Since the start of 2010, GlaxoSmithKline has progressed ten new compounds and vaccines into Phase III clinical trials. It also boasts a pipeline of approximately 30 late-stage assets.